Democrats’ New Wave Leads Attack On Pharma At Drug Pricing Hearing
Executive Summary
The last quarter of the four-hour hearing may be a warning of things to come for pharma if the newer guard of Democrats keeps gaining traction among voters and power in Congress.
You may also be interested in...
US Patent Reform Legislation Threatened By Biden Support For Vaccine IP Waiver, Republicans Say
At hearing on Humira patent thicket, House Republicans express concern that Democrats’ support for transferring US intellectual property rights for COVID-19 vaccines to other countries is a bad sign for collaboration on legislation to reform patent abuses.
Pharma Catches A Break As Democrats Stumble In Rollout Of Pricing Investigation
House Oversight Committee plans to grill more companies on pricing later this year, but rushed rollout of reports from a long-running investigation, combined with competing higher profile news events, seemed to dampen the blow of the latest drug pricing scrutiny. Democrats failed to offer any new, unified solutions for their grievances with industry, while Republicans largely rushed to pharma’s defense.
FDA’s Authority Looks Safe From Judicial Interference Following Supreme Court Abortion Pill Arguments
The agency's and the pharma industry’s worst fears – that a potential ruling in the mifepristone case might usurp the FDA’s scientific authority and throw the stability of the US drug approval process into question – seem unlikely to materialize as the majority of the Supreme Court justices signal the Alliance for Hippocratic Medicine lacks standing to sue.